{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:48:58Z","timestamp":1773085738078,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.clinthera.2022.09.013","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T09:42:30Z","timestamp":1666950150000},"page":"1463-1470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Bilateral Effect of OC-01 (Varenicline Solution) Nasal Spray for Treatment of Signs and Symptoms in Individuals with Mild, Moderate, and Severe Dry Eye Disease"],"prefix":"10.1016","volume":"44","author":[{"given":"James","family":"Katz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"Periman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sathi","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Sarnicola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandy","family":"Hemphill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan G.","family":"Kabat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura H.","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puja","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1655-6973","authenticated-orcid":false,"given":"Andrea","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.09.013_bib0001","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology Report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf."},{"issue":"23","key":"10.1016\/j.clinthera.2022.09.013_bib0002","doi-asserted-by":"crossref","first-page":"9271","DOI":"10.3390\/ijms21239271","article-title":"Defining Dry Eye from a Clinical Perspective","volume":"21","author":"Tsubota","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.clinthera.2022.09.013_bib0003","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1016\/j.jprot.2012.04.053","article-title":"In-Depth Analysis of the Human Tear Proteome","volume":"75","author":"Zhou","year":"2012","journal-title":"J Proteomics"},{"issue":"2","key":"10.1016\/j.clinthera.2022.09.013_bib0004","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1194\/jlr.M044826","article-title":"Extensive Characterization of Human Tear Fluid Collected Using Different Techniques Unravels the Presence of Novel Lipid Amphiphiles","volume":"55","author":"Lam","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2022.09.013_bib0005","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.2147\/OPTH.S279051","article-title":"A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments","volume":"14","author":"Periman","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.09.013_bib0006","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18433\/jpps29895","article-title":"Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program","volume":"22","author":"Chan","year":"2019","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.clinthera.2022.09.013_bib0007","unstructured":"FDA: Tyrvaya Prescribing Information [Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/213978s000lbl.pdf."},{"key":"10.1016\/j.clinthera.2022.09.013_bib0008","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/ICO.0000000000002941","article-title":"ONSET-1 Phase 2b Randomized Trial to Evaluate the Safety and Efficacy of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease","volume":"41","author":"Wirta","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.clinthera.2022.09.013_bib0009","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ophtha.2021.11.004","article-title":"Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease: the ONSET-2 Phase 3, Randomized Trial","volume":"129","author":"Wirta","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2022.09.013_bib0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtos.2021.12.007","article-title":"A Phase II Randomized Trial to Evaluate the Long-Term (12-Week) Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray for Dry Eye Disease: The MYSTIC Study","volume":"24","author":"Quiroz-Mercado","year":"2021","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2022.09.013_bib0011","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jtos.2019.08.012","article-title":"Chronic Electrical Stimulation for Tear Secretion: Lacrimal vs. Anterior Ethmoid Nerve","volume":"17","author":"Kossler","year":"2019","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2022.09.013_bib0012","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1167\/iovs.16-21362","article-title":"Enhanced Tearing by Electrical Stimulation of the Anterior Ethmoid Nerve","volume":"58","author":"Brinton","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2022.09.013_bib0013","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jtos.2014.02.002","article-title":"Rethinking Dry Eye Disease: a Perspective on Clinical Implications","volume":"12","author":"Bron","year":"2014","journal-title":"Ocul Surf"},{"key":"10.1016\/j.clinthera.2022.09.013_bib0014","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jtos.2017.05.009","article-title":"TFOS DEWS II Clinical Trial Design Report","volume":"15","author":"Novack","year":"2017","journal-title":"Ocul Surf."},{"key":"10.1016\/j.clinthera.2022.09.013_bib0015","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/OPTH.S152841","article-title":"Ocular Comfort Assessment of Lifitegrast Ophthalmic Solution 5.0% in OPUS-3, A Phase III Randomized Controlled Trial","volume":"12","author":"Nichols","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.09.013_bib0016","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2020.03.044","article-title":"Patient-Reported Burden of Dry Eye Disease in the United States: Results of an Online Cross-Sectional Survey","volume":"216","author":"Dana","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.09.013_bib0017","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2022.09.013_bib0018","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","article-title":"Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3)","volume":"124","author":"Holland","year":"2017","journal-title":"Ophthalmology"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822003459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822003459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:57:34Z","timestamp":1758963454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822003459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0149291822003459"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.09.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bilateral Effect of OC-01 (Varenicline Solution) Nasal Spray for Treatment of Signs and Symptoms in Individuals with Mild, Moderate, and Severe Dry Eye Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}